DHSC) relating to coronavirus (COVID-19) treatments and clinical trials.For more information, see:Added 'Higher-risk patients eligible for COVID-19 treatments: independent advisory group report (March 2023)' to the expert advice section.Renamed and updated document collection to reflect the closure of the Antivirals and Therapeutics Taskforce on 31 March 2023.Added information under 'Protection' including a link to the Evusheld evaluation.Added new 'Protection' section containing links to pages on the RAPID C-19 Oversight Group report into Evusheld and letter to patient groups on the decision not to procure Evusheld.First published..